Exciting updates on Priovant’s non-infectious uveitis (NIU) program:
Priovant Therapeutics
Biotechnology Research
Durham, NC 3,675 followers
Developing targeted therapies for patients with severe autoimmune disease
About us
Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the heaviest patient burdens. We are rapidly developing a pipeline of medicines targeted to the specific molecular dysregulations underlying severe autoimmune conditions, unlocking new treatment options for patients who are underserved by existing therapies.
- Website
-
https://priovanttx.com
External link for Priovant Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Durham, NC
- Type
- Privately Held
Locations
-
Primary
Get directions
Durham, NC, US
Employees at Priovant Therapeutics
-
Vandana Mathur, MD FASN
Clinical Drug Development and Strategy Consultant, Transplant Nephrologist and Clinical Trialist with broad range of experience including nephrology,…
-
Beth Anne Lang
Senior Vice President, Regulatory Affairs
-
Jennifer McDaniel
Director, Clinical Data Management at Priovant Therapeutics
-
Bruce Stevens
Senior Vice President, Quality
Updates
-
Priovant Therapeutics reposted this
Priovant is excited to report finishing enrollment for the Phase 3 VALOR study of brepocitinib in dermatomyositis:
-
Excited to share our positive data for brepocitinib in non-infectious uveitis (NIU): https://lnkd.in/exqepsH3